Abstract:Retinitis pigmentosa (RP) is the most genetically and phenotypically heterogeneous disorder, characterized by the progressive death of photoreceptor cells. In recent years, huge advances have been made in understanding the disease mechanisms, identifying causal genes, and developing therapeutic strategies for this disorder. This special issue updates the knowledge of RP and presents original clinical and experimental research. Photoreceptor cell death is known to be characterized at the early stage by caspase dependent or independent apoptosis and at late stage by necrosis, but the molecular mechanisms are not fully understood. In this special issue, S. R. Patnaik et al. review the functional role of RPGR protein complex in the pathogenesis of RP. Disease mechanisms are further elucidated in mouse (Q. Zheng et al.) and zebrafish models (Y. Liu et al. and S. Akhtar et al.). R. Migliorini et al. discuss RP associated syndromes, such as impaired ocular motility. E. Strobbe et al. report a correlation between ocular inflammation and endothelin (ET-1) plasma levels in early RP patients and suggest that anti-inflammatory therapy may slow the progression of RP. With the development of new technologies such as next generation sequencing (NGS), more and more mutant genes that cause retinal degenerative diseases have been found. B. Gong et al. reported here a recessive RDH12 mutation identified by exome sequencing in severe early onset RP patients, which further verifies the application of NGS for molecular diagnosis of RP. Meanwhile, many naturally occurring or genetically engineered animal models have shown gene mutations and phenotypes similar to human inherited retinal diseases, which has led to the development of a variety of therapeutic strategies for those inherited diseases regarded traditionally as incurable. Following the success of Leber congenital amaurosis 2 (LCA2) gene therapy clinical trials, more and more vector based gene therapy clinical trials have been performed on a variety of retinal conditions including RP with MERTK mutation. AAV-mediated gene replacement therapy shows great potential to treat patients in the early stage of the disease. Gene replacement therapy combined with other approaches like treatment with histone deacetylases inhibitors (reviewed by H. Zhang et al.) or antiapoptotic/inflammatory chemicals or natural products, which can extend the therapeutic window in middle to late stages of those patients, is a potentially promising strategy for improving photoreceptor function and significantly slowing the process of retinal degeneration. Cell replacement is a promising therapeutic strategy for RP. Successful cell replacement treatments have been done in RP animal models, providing hope for RP patients and their families. Chinese medicine has a long history in the treatment of RP; combinational treatment of Chinese medicine with Western medicine may further reduce the progression of RP (reviewed by J. Xu and Q. Peng). Xinhua Shu Ji-jing Pang Houbin Zhang David Mansfield

Retinal Organoids and Microfluidic Chip-Based Approaches to Explore the Retinitis Pigmentosa with USH2A Mutations

Modeling Retinitis Pigmentosa: Retinal Organoids Generated From the iPSCs of a Patient With the USH2A Mutation Show Early Developmental Abnormalities.

Molecular pathology of Usher 1B patient-derived retinal organoids at single cell resolution

Human retinal organoids harboring IMPG2 mutations exhibit a photoreceptor outer segment phenotype that models advanced retinitis pigmentosa

Gene Correction Reverses Ciliopathy and Photoreceptor Loss in Ipsc-Derived Retinal Organoids from Retinitis Pigmentosa Patients

Systematic Evaluation Of A Targeted Gene Capture Sequencing Panel For Molecular Diagnosis Of Retinitis Pigmentosa

Modeling PRPF31 retinitis pigmentosa using retinal pigment epithelium and organoids combined with gene augmentation rescue

Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies

Modeling autosomal dominant retinitis pigmentosa by using patient-specific retinal organoids with a class-3 RHO mutation

Retinal Organoid Models Show Heterozygous Rhodopsin Mutation Favors Endoplasmic Reticulum Stress-Induced Apoptosis in Rods

Targeted next generation sequencing identified novel mutations in RPGRIP1 associated with both retinitis pigmentosa and Leber's congenital amaurosis in unrelated Chinese patients.

Establishment of Non-Integrate Induced Pluripotent Stem Cell Line CSUASOi006-A, from Urine-Derived Cells of a PRPF8-related Dominant Retinitis Pigmentosa Patient

Retinitis Pigmentosa: Disease Mechanisms, Diagnosis, and Therapies

Human iPSC-derived RPE and retinal organoids reveal impaired alternative splicing of genes involved in pre-mRNA splicing in PRPF31 autosomal dominant retinitis pigmentosa

Soluble CX3CL1-expressing retinal pigment epithelium cells protect rod photoreceptors in a mouse model of retinitis pigmentosa

Aberrant Retinal Pigment Epithelial Cells Derived from Induced Pluripotent Stem Cells of a Retinitis Pigmentosa Patient with the PRPF6 Mutation

Modeling Retinitis Pigmentosa Through Patient-Derived Retinal Organoids

Protective effects of human iPS-derived retinal pigmented epithelial cells on retinal degenerative disease

Multimodal Imaging and Genetic Characteristics of Chinese Patients with USH2A-Associated Nonsyndromic Retinitis Pigmentosa

Establishment of Induced Pluripotent Stem Cell Line CSUASOi003- A from an Autosomal Recessive Retinitis Pigmentosa Patient Carrying Compound Heterozygous Mutations in CRB1 Gene

Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation